{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:52Z","timestamp":1781636092883,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sporadic hemangioblastomas (sHBs) are less prevalent than those in von Hippel-Lindau (VHL) disease. Surgical resection and radiation therapy remain the standard treatments, and medical treatment options for sHBs are limited. While belzutifan shows a favorable response in VHL-associated HBs, its efficacy in sHBs is uncertain. We present a case of probable belzutifan-induced tumor reduction in a patient with sHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We present a case of a 65-year-old man with progressive right-sided hemifacial paresthesia, retro-orbital pain, and periorbital edema, subsequently diagnosed with progressive right trigeminal nerve-associated sHB. The patient did not meet clinical or genetic criteria for VHL disease. Serial magnetic resonance imaging (MRI) demonstrated significant tumor progression over seven years. Treatment included 12.5\u2009Gy of radiation in 2016, subtotal resection in 2021, and re-radiation with 50.6\u2009Gy in 2022. Repeat debulking resection was deemed high-risk due to tumor location, and prior treatment precluded further re-radiation. Following multidisciplinary review and patient preference, medical therapy was pursued, and belzutifan at 120\u2009mg\/day was initiated. MRI demonstrated tumor reduction from 3.4\u2009cm to 3.1\u2009cm by month 2. Due to anemia and fatigue, belzutifan was reduced and continued at 80\u2009mg\/day with stable hemoglobin above 10.0 and tolerable fatigue. Serial brain MRIs showed a durable tumor reduction, with a \u22127.00\u2009mm\/year median linear growth rate reduction by month 13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report of belzutifan treatment for sHB, resulting in tumor reduction. Belzutifan may offer a possible treatment option for residual, progressive, and\/or pre-surgical sHBs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05466-x","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:43:15Z","timestamp":1771087395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review"],"prefix":"10.1007","volume":"176","author":[{"given":"Rebekka E.","family":"Hooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niket","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Willy L.","family":"Mondia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Mantziaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Vi","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Mut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok R.","family":"Asthagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-6062","authenticated-orcid":false,"given":"Benjamin W.","family":"Purow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"5466_CR1","unstructured":"Khan MM, Hemangioblastoma BS in: (2024) StatPearls. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606126\/. Accessed December 10, 2024"},{"key":"5466_CR2","doi-asserted-by":"publisher","first-page":"570103","DOI":"10.3389\/fonc.2020.570103","volume":"10","author":"X Yin","year":"2020","unstructured":"Yin X, Duan H, Yi Z, Li C, Lu R, Li L (2020) Incidence, prognostic factors and survival for hemangioblastoma of the central nervous System: analysis based on the surveillance, epidemiology, and end Results database. Front Oncol 10:570103. https:\/\/doi.org\/10.3389\/fonc.2020.570103","journal-title":"Front Oncol"},{"issue":"9","key":"5466_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/neuonc\/nox034","volume":"19","author":"S Takayanagi","year":"2017","unstructured":"Takayanagi S, Mukasa A, Tanaka S et al. (2017) Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system. Neuro-Oncol 19(9):1228\u20131236. https:\/\/doi.org\/10.1093\/neuonc\/nox034","journal-title":"Neuro-Oncol"},{"key":"5466_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.wneu.2023.02.071","volume":"173","author":"D Jankovic","year":"2023","unstructured":"Jankovic D, Vuong K, Splavski B, Rotim K, Arnautovic KI (2023) Supratentorial hemangioblastoma in adults: a Systematic review and comparison of infratentorial and spinal cord locations. World Neurosurg 173:48\u201362. https:\/\/doi.org\/10.1016\/j.wneu.2023.02.071","journal-title":"World Neurosurg"},{"issue":"5","key":"5466_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","volume":"120","author":"RR Lonser","year":"2014","unstructured":"Lonser RR, Butman JA, Huntoon K et al. (2014) Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 120(5):1055\u20131062. https:\/\/doi.org\/10.3171\/2014.1.JNS131431","journal-title":"J Neurosurg"},{"key":"5466_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.wneu.2024.08.032","volume":"191","author":"D Jankovic","year":"2024","unstructured":"Jankovic D, Selimovic E, Kuharic M, Splavski B, Rotim K, Arnautovic KI (2024) Understanding Adult central nervous System hemangioblastomas: a Systematic review. World Neurosurg 191:119\u2013127. https:\/\/doi.org\/10.1016\/j.wneu.2024.08.032","journal-title":"World Neurosurg"},{"key":"5466_CR7","doi-asserted-by":"publisher","first-page":"1092140","DOI":"10.3389\/fsurg.2022.1092140","volume":"9","author":"L Chen","year":"2022","unstructured":"Chen L, Xiong Z, Zhou Y et al. (2022) Clinical characteristics, surgical management, and prognostic factors for supratentorial hemangioblastoma: a retrospective study. Front Surg 9:1092140. https:\/\/doi.org\/10.3389\/fsurg.2022.1092140","journal-title":"Front Surg"},{"issue":"3","key":"5466_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","volume":"4","author":"N Varshney","year":"2017","unstructured":"Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS (2017) A review of Von Hippel-Lindau syndrome. J Kidney Cancer VHL 4(3):20\u201329. https:\/\/doi.org\/10.15586\/jkcvhl.2017.88","journal-title":"J Kidney Cancer VHL"},{"key":"5466_CR9","doi-asserted-by":"publisher","unstructured":"Busch NL, Cruz AM, Herbst J et al. Trigeminal nerve hemangioblastoma in the setting of undiagnosed von Hippel-Lindau disease: illustrative case. https:\/\/doi.org\/10.3171\/CASE24149. Published online July 29, 2024","DOI":"10.3171\/CASE24149"},{"issue":"6","key":"5466_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.surneu.2006.08.085","volume":"67","author":"F Roberti","year":"2007","unstructured":"Roberti F, Jones RV, Wright DC (2007) Cranial nerve hemangioblastomas. Report of a rare case and review of literature. Surg Neurol 67(6):640\u2013646. https:\/\/doi.org\/10.1016\/j.surneu.2006.08.085","journal-title":"Surg Neurol"},{"issue":"6","key":"5466_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.37349\/en.2023.00031","volume":"2","author":"C Sanghadia","year":"2023","unstructured":"Sanghadia C, Martinez ME, McNulty M et al. (2023) Emerging therapies of hemangioblastomas. Explor Neurosci 2(6):318\u2013330. https:\/\/doi.org\/10.37349\/en.2023.00031","journal-title":"Explor Neurosci"},{"key":"5466_CR12","doi-asserted-by":"publisher","unstructured":"Curry L, Soleimani M Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future Oncol 20(18):1251\u20131266. https:\/\/doi.org\/10.2217\/fon-2023-0679","DOI":"10.2217\/fon-2023-0679"},{"issue":"5","key":"5466_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2021.1925248","volume":"30","author":"E Hasanov","year":"2021","unstructured":"Hasanov E, Jonasch E (2021) MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opin Investig Drugs 30(5):495\u2013504. https:\/\/doi.org\/10.1080\/13543784.2021.1925248","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"5466_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/biomedicines6010035","volume":"6","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang Q (2018) VHL and Hypoxia signaling: beyond HIF in Cancer. Biomedicines 6(1):35. https:\/\/doi.org\/10.3390\/biomedicines6010035","journal-title":"Biomedicines"},{"issue":"22","key":"5466_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O et al. (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 385(22):2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"N Engl J Med"},{"issue":"22","key":"5466_CR16","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","volume":"28","author":"J Fallah","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C et al. (2022) FDA approval summary: Belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res Off J Am Assoc Cancer Res 28(22):4843\u20134848. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1054","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"5466_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos O, Iversen AB, Narayan V et al. (2024) Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 25(10):1325\u20131336. https:\/\/doi.org\/10.1016\/S1470-2045(24)00389-9","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"5466_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2023.41.16_suppl.2078","volume":"41","author":"O Iliopoulos","year":"2023","unstructured":"Iliopoulos O, Rapalino O, Barker FG et al. (2023) Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): a single institution experience. J Clin Oncol 41(16_suppl):2078\u20132078. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2078","journal-title":"J Clin Oncol"},{"issue":"1","key":"5466_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40478-014-0167-x","volume":"2","author":"GM Shankar","year":"2014","unstructured":"Shankar GM, Taylor-Weiner A, Lelic N et al. (2014) Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun 2(1):167. https:\/\/doi.org\/10.1186\/s40478-014-0167-x","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"5466_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP et al. (2021) Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 27(5):802\u2013805. https:\/\/doi.org\/10.1038\/s41591-021-01324-7","journal-title":"Nat Med"},{"issue":"8","key":"5466_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K et al. (2024) Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med 391(8):710\u2013721. https:\/\/doi.org\/10.1056\/NEJMoa2313906","journal-title":"N Engl J Med"},{"issue":"3","key":"5466_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4132\/jptm.2022.04.13","volume":"56","author":"RA Yoda","year":"2022","unstructured":"Yoda RA, Cimino PJ (2022) Neuropathologic features of central nervous system hemangioblastoma. J Pathol Transl Med 56(3):115\u2013125. https:\/\/doi.org\/10.4132\/jptm.2022.04.13","journal-title":"J Pathol Transl Med"},{"key":"5466_CR23","doi-asserted-by":"publisher","unstructured":"Sugiyama Y, Kuramitsu S, Eguchi K et al. (2024) Time course of tumorigenesis of a newly developed sporadic hemangioblastoma in an elderly patient: illustrative case. J Neurosurg Case Lessons 7(15): CASE23757. doi: https:\/\/doi.org\/10.3171\/CASE23757","DOI":"10.3171\/CASE23757"},{"key":"5466_CR24","doi-asserted-by":"publisher","unstructured":"Kord Valeshabad A, Xiao L, Amin-Hanjani S, Alsadi A, Valyi-Nagy T, Kim J (2018) Sporadic hemangioblastoma of the cavernous sinus and Meckel\u2019s cave. J Neurol Surg Rep 79(4):e98\u2013e102. https:\/\/doi.org\/10.1055\/s-0038-1676455","DOI":"10.1055\/s-0038-1676455"},{"key":"5466_CR25","doi-asserted-by":"publisher","unstructured":"Dang D, Gilbert O, Vyas N (2022) Not All nerve sheath tumors are schwannomas: case report of a rare Meckel\u2019s cave hemangioblastoma and review of the literature. In: Journal of neurological surgery part B: skull Base. Vol 83. Georg Thieme Verlag KG, p P160. https:\/\/doi.org\/10.1055\/s-0042-1744009","DOI":"10.1055\/s-0042-1744009"},{"issue":"1","key":"5466_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10143-023-02194-y","volume":"46","author":"Y Laviv","year":"2023","unstructured":"Laviv Y, Saraf D, Oxman L, Zvi IB (2023) Supratentorial hemangioblastoma: correlation between phenotype, gender and vascular territory affected. Neurosurg Rev 46(1):281. https:\/\/doi.org\/10.1007\/s10143-023-02194-y","journal-title":"Neurosurg Rev"},{"key":"5466_CR27","doi-asserted-by":"publisher","first-page":"110879","DOI":"10.1016\/j.jocn.2024.110879","volume":"129","author":"SM Tos","year":"2024","unstructured":"Tos SM, Hajikarimloo B, Mantziaris G et al. (2024) Comparative analysis of stereotactic radiosurgery outcomes for supratentorial hemangioblastomas in von hippel-lindau disease and sporadic cases: a multi-center international study. J Clin Neurosci 129:110879. https:\/\/doi.org\/10.1016\/j.jocn.2024.110879","journal-title":"J Clin Neurosci"},{"issue":"5","key":"5466_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0046-8177(97)90075-7","volume":"28","author":"AO Vortmeyer","year":"1997","unstructured":"Vortmeyer AO, Gnarra JR, Emmert-Buck MR et al. (1997) von Hippel-Lindau Gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28(5):540\u2013543. https:\/\/doi.org\/10.1016\/S0046-8177(97)90075-7","journal-title":"Hum Pathol"},{"issue":"8","key":"5466_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860\u2013867. https:\/\/doi.org\/10.1038\/ng.2699","journal-title":"Nat Genet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05466-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:09Z","timestamp":1781633829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05466-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5466"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05466-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}